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Abstract
Rationale: Alveolar macrophages (AMs) play a key role in host
defense to inhaled bacterial pathogens, in part by secreting
inflammatory mediators. Cystic fibrosis (CF) airways exhibit a
persistent, robust inflammatory response that may contribute to the
pathophysiology of CF. Recent findings have linked endoplasmic
reticulum stress responses mediated by inositol-requiring enzyme
1a–dependentmessengerRNAsplicing (activation)ofX-box–binding
protein-1 (XBP-1s) to inflammation in peripheral macrophages.
However, the role of XBP-1s in CF AM function is not known.
Objectives: To evaluate inflammatory responses of AMs from
chronically infected/inflamed human CF lungs and test whether
XBP-1s is required for AM-mediated inflammation.
Methods: Basal and LPS-induced inflammatory responses were
evaluated in primary cultures of non-CF versus CFAMs. XBP-1s was
measured and its function was evaluated in AMs using 8-formyl-7-
hydroxy-4-methylcoumarin (4m8C), an inhibitor of inositol-
requiring enzyme 1a–dependent XBP-1s, and in THP-1 cells stably
expressing XBP-1 shRNA, XBP-1s, or a dominant-negative XBP-1.
Measurements andMainResults:CFAMs exhibited exaggerated
basal and LPS-induced production of tumor necrosis factor-a and
IL-6, and these responses were coupled to increased levels of XBP-1s.
In non-CF and CF AMs, LPS-induced cytokine production was
blunted by 4µ8C. A role for XBP-1s in AM inflammatory responses
was further established by data from dTHP-1 cells indicating that
expression of XBP-1 shRNA reduced XBP-1s levels and LPS-induced
inflammatory responses; and LPS-induced inflammation was up-
regulated by expression of XBP-1s and inhibited by dominant-
negative XBP-1.
Conclusions: These findings suggest that AMs contribute to the
robust inflammation of CF airways via an up-regulation of XBP-1s-
mediated cytokine production.
Keywords: cystic fibrosis; airway inflammation; alveolar
macrophage; UPR; IRE1a/XBP-1
Cystic fibrosis (CF) airway disease is
characterized by a chronic and robust
inflammatory state often termed
hyperinflammatory. In CF airways,
the functional absence of the CF
transmembrane conductance regulator
(CFTR) results in an abnormal airway
surface liquid hydration, adherence of
thickened mucus to airway surfaces, and
persistent airway infection leading to
chronic inflammation (1, 2). As evidence of
the robust inflammation in CF airways,
cytokines and neutrophil elastase are
elevated in sputa from patients with CF
versus without CF (3). In particular, levels
of proinflammatory cytokines and
inflammatory cells triggered by bacterial
infection are higher in patients with CF
versus without CF with acute lung infection
(4–6), including the cytokines tumor
necrosis factor (TNF)-a, IL-1b, IL-6, and
IL-8 (7–10).
Alveolar macrophages (AMs) represent
a first line of defense against inhaled
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pathogens, including Pseudomonas
aeruginosa (11), via phagocytosis of
pathogens and secretion of inflammatory
mediators. Like neutrophils, persistent
activation of AMs without resolution of
infection could lead to lung damage. In one
scenario, chronic exposure of AMs to the
products of persistent intraluminal
infection could produce AM-mediated lung
damage. A second scenario has suggested
that CFTR is expressed in AMs and loss of
functional CFTR results in specific defects
in AM function (12–17), including
impaired bacterial killing linked to CFTR
endolysosomal dysfunction (16, 18, 19) and
alterations in inflammatory responses of
AMs. Evidence for this scenario is provided
by studies demonstrating that AMs from
CFTR2/2 mice exhibit exaggerated
inflammatory responses to bacterial LPS
(14), and inhibition or mutation of CFTR
enhances production of cytokines in
murine AMs (20). Moreover, CFTR1/2
mice release larger amounts of IL-6 in
response to transforming growth factor-b,
as compared with wild-type mice (21). In
agreement with the murine data, silencing
of CFTR in human AMs results in
increased secretion of IL-8 (22). These data
suggest that human CF AMs might have
abnormal function and contribute to an
increased inflammatory response.
Inflammation of CF airway epithelia
induces endoplasmic reticulum (ER) stress,
which triggers the unfolded protein
response (UPR) (23–26). Eukaryotic cells
exhibit three UPR pathways: (1) inositol-
requiring enzyme 1 (IRE1), which exists
in two isoforms, a (ubiquitous) and b
(present in mucous cells of the gut and
respiratory tracts); (2) activating
transcription factor 6; and (3) PKR-like ER
kinase/pancreatic eIF2a kinase (24, 27, 28).
In normal airways, the UPR constitutes
an adaptive response to ER stress that
provides cellular protection and survival.
For instance, activation of IRE1a induces
splicing (activation) of the mRNA of
X-box–binding protein-1 (XBP-1s) (29, 30).
XBP-1s is a transcription factor that up-
regulates the ER protein folding capacity
and expands the secretory pathway,
facilitating increased production of
inflammatory mediators involved in
innate defense (24–26). In contrast, in
obstructed CF airways, persistent high
levels of ER stress can have a detrimental
effect for airway homeostasis, including
high levels of cytokine production that may
mediate inflammation-induced airway
wall damage.
Activation of the IRE1a-dependent
XBP-1s pathway has been linked to
cytokine production in macrophages from
murine bone marrow or peripheral human
monocytes (31). We hypothesized that
IRE1a-mediated XBP-1s is required for
AM cytokine production and activation of
IRE1a-dependent XBP-1s is increased in
CF AMs. Hence, this study addressed
whether inflammatory responses are larger
in primary cultures of AMs from CF versus
noninfected/inflamed human lungs, and
the role of IRE1a-dependent XBP-1s in
inflammatory responses of non-CF and CF
AMs. Some results from this study have
been reported in the form of an abstract at
the 2014 North American Cystic Fibrosis
Conference (32).
Methods
For further details on the applied methods,
see the online supplement.
Isolation and Culture of Primary
Human AMs
Lungs were lavaged with phosphate-
buffered saline (PBS) and the retrieved fluid
centrifuged (2503 g for 10 min; 48C). The
cell pellet was resuspended in macrophage
medium. AM isolation was performed as
previously described (33). Non-CF and CF
AMs were seeded onto 12-well plates




THP-1 human monocytic cells were
exposed to 50 ng/ml of phorbol 12-myristate
13-acetate in the culture medium for
72 hours.
THP-1 Cells Expressing shRNA
Targeting XBP-1
THP-1 cells were infected with a control
shRNA or an anti–XBP-1 shRNA lentiviral
vector. Positive cells were selected with
1 mg/ml puromycin.
Stable Expression of Control, XBP-1s,
and Dominant Negative XBP-1
Vectors
THP-1 cells were infected with a control
retroviral vector or retroviral vectors
containing XBP-1s or dominant-negative
XBP-1 (DN-XBP-1). Positive cells were
selected with 200 mg/ml neomycin G418.
Immunohistochemistry
Cytocentrifuge slides were fixed with 4%
paraformaldehyde, blocked with 1% bovine
serum albumin in PBS with 0.1% Tween-20,
incubated overnight at 48C with a HAM-56
antibody, followed by incubation with a
secondary antibody for 1 hour at room
temperature.
Flow Cytometry
One hundred thousand 3-day-old cells were
incubated for 30 minutes at 48C with
anti–CD11c-APC and/or anti–CD163-
PerCP/Cy5.5 conjugated antibody. Data were
analyzed using FlowJo X.0.7 (Ashland, OR).
At a Glance Commentary
Scientific Knowledge on the
Subject: Alveolar macrophages
(AMs) play a crucial role in pulmonary
innate defense in part by secreting
inflammatory mediators. The specific
contribution of AMs to inflammatory
responses observed in cystic fibrosis
(CF) lung disease and the mechanisms
underlying these responses are not
well-established. The unfolded protein
response mediated by activation of the
inositol-requiring enzyme 1 (IRE1)-
a–dependent X-box–binding protein-1
(XBP-1) pathway has been
implicated in CF airway epithelial
inflammation. However, the functional
role of IRE1a/XBP-1 in inflammatory
responses of AMs from CF lungs is not
known.
What This Study Adds to the
Field: This study indicates that
primary cultures of human CF AMs
exhibit a robust production of
inflammatory mediators, and this
response reflects an adaptation to the
infectious/inflammatory environment
of CF airways. The exaggerated
response of CF AMs to LPS is mediated
by activation of the IRE1a/XBP-1 arm
of the unfolded protein response. Our
findings offer the proof-of-concept
that manipulation of the IRE1a/XBP-1
pathway in AMs may provide new
therapeutic opportunities for CF
airways disease.
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Treatment with Pharmacologic
Agents
AMswere washed with PBS and treated with
100 ng/ml LPS from P. aeruginosa.
CFTRinh-172 (3-[(3-trifluoromethyl)
phenyl]-5-[(4-carboxyphenyl)methylene]-
2-thioxo-4-thiazolidinone) was used at the
concentration of 10 mM. 8-Formyl-7-
hydroxy-4-methylcoumarin (4m8C), an
IRE1a inhibitor, was used at the
concentration of 50 mM.
Treatment with Supernatant of
Mucopurulent Material
Mucopurulent material was harvested
from the airways of human CF lungs and
processed as previously described
(23–25, 34). Filtered supernatant from
mucopurulent material (SMM) was pooled
from five CF lungs. Non-CF AMs were
exposed to 30 ml of PBS or SMM (1:3
dilution in culture medium) for 3 hours.
Quantitative Real-Time Polymerase
Chain Reaction
RNA isolation, cDNA preparation, and real-
time polymerase chain reaction were
performed as previously described (27).
mRNA values were normalized to 18S
mRNA values.
ELISA Assays
TNF-a and IL-6 secretion was evaluated by
ELISA.
Statistical Analysis
Data are reported as mean6 SD with a
P value less than 0.05 considered statistically
significant.
Results
Isolation and Characterization of AMs
AM isolation and their attachment to plastic
dishes was performed as previously described
(33). Each lung tissue yielded 2–203 106
AMs, which consisted mostly of large, round
cells heterogeneous in size, as observed by
light microscopy (Figure 1A). AM evaluation
using Diff-Quik (Polysciences, Inc.,
Warrington, PA) indicated that the
preparation consisted of more than 99% AMs
(Figure 1B). The purity of the AM samples
was further indicated by the expression of the
macrophage marker HAM-56 (35) in all
isolated cells (Figure 1C).
Flow cytometry was next performed to
establish the purity of the AMs. The
preparations were analyzed according to
their forward scatter characteristics, and for
their expression of CD1631 and CD11c1
(Figure 1D, left and middle). CD163 is
expressed exclusively on monocytes and
macrophages (36), and CD11c is expressed
on many monocytic-derived cells, including
macrophages (37). The combination of
CD11c1 and CD1631 expression, which is
necessary and sufficient to accurately
distinguish macrophages from other lung
cells, indicates that our isolation procedure
yielded a highly purified preparation of
AMs (Figure 1D, right).
Primary Cultures of CF AMs Express a
Robust Inflammatory Phenotype
We next evaluated the basal and LPS-
induced cytokine production in non-CF
versus CF AMs in primary cultures for 3
days. Treatment with vehicle (0.1% dimethyl
sulfoxide) did not affect the expression of
inflammatory markers, as compared with
untreated AMs (data not shown). Therefore,
cytokine values obtained under vehicle
treatment were considered baseline values.
We first compared the baseline mRNA
levels of TNF-a and IL-6 in primary
cultures of CF versus non-CF AMs. These
inflammatory mediators were evaluated
because of their relevance to CF airways
disease (7, 8). Under baseline conditions,
CF AMs exhibited 25- and 24-fold higher
mRNA levels of TNF-a and IL-6, as
compared with non-CF AMs (Figures 2A
and 2B). We then determined the effect of













































Figure 1. Characterization of alveolar macrophages (AMs) isolated from resected human lungs. (A)
Adherent cells were isolated as described in the METHODS. Examination of cell morphology by phase-
contrast inverted light microscopy. (B) Morphology of sedimented AMs. Cells were sedimented onto
slides (cytospin), stained (Diff-Quik), and examined by light microscopy. (C) Immunofluorescence
microscopy of AMs. Green =macrophage migration inhibitor factor HAM-56 (human macrophage
marker). Blue = nuclei stain with 4’6-diamidino-2-phenylindole (DAPI). (D) Flow cytometric analysis of
AMs. The preparations were analyzed according to their forward scatter characteristics (FSC), CD163
(macrophage marker), and CD11c (macrophage marker) expression in human AMs. Number in right
panel indicates the percentage of cells positive for the macrophage markers. Scale bars = 100 mm.
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levels of TNF-a and IL-6 in CF and non-CF
AMs. Pilot studies indicated that 100 ng/ml
LPS was a maximal dose for inducing
cytokine mRNA expression and secretion
(see Figure E1 in the online supplement).
Moreover, 6-hour LPS led to maximal
cytokine mRNA up-regulation associated
with increased cytokine secretion (see
Figure E2). The 100 ng/ml (6-h treatment)
LPS-up-regulated TNF-a and IL-6 mRNA
levels were higher in CF versus non-CF
AMs (Figures 2A and 2B).
To address whether the higher mRNA
expression of TNF-a and IL-6
corresponded to higher TNF-a and IL-6
protein levels, the secretion of TNF-a and
IL-6 was evaluated. Under basal conditions,
CF AMs secreted 175- and 260-fold higher
levels of TNF-a and IL-6 than non-CF
AMs (Figures 2C and 2D). In addition,
LPS-up-regulated TNF-a and IL-6
secretion was 49-fold and sevenfold higher
in CF versus non-CF AMs (Figures 2C and
2D). These data indicate that CF AMs
exhibit a greater inflammatory phenotype
than non-CF AMs under basal condition
and following LPS exposure.
CFTR Expression Levels in Human
AMs
Because it has been suggested that
macrophages express CFTR at a low, but
functional level (12), we addressed whether
the absence of CFTR function is coupled to
the robust inflammatory response of CF
AMs. We first evaluated CFTR expression
in primary non-CF AMs from human lungs
versus primary human bronchial epithelial
(HBE) cells known to express CFTR. CFTR
mRNA levels were very low in AMs as
compared with HBE cells (Figure 3).
Notably, the low CFTR expression levels in
AMs did not differ from the hypothetical
value zero, based on one-sample t test
(Figure 3). These data suggest that primary
cultures of human AMs either do not
express CFTR or their CFTR expression is
extremely low.
The putative very low level of CFTR
expression in non-CF AMs could be,
nevertheless, important for AM function.
Hence, we considered that the loss of
functional CFTR in CF AMs could be












































































































Figure 2. Primary cultures of cystic fibrosis (CF) alveolar macrophages (AMs) exhibit robust basal and LPS-induced tumor necrosis factor (TNF)-a and
IL-6 production. Non-CF and CF AMs were stimulated for 6 hours with 0.1% dimethyl sulfoxide (vehicle) or 100 ng/ml LPS from Pseudomonas aeruginosa.
Levels of TNF-a (A) and IL-6 (B) mRNA were determined by quantitative reverse transcriptase polymerase chain reaction and
expressed as fold change relative to 18SmRNA. TNF-a (C) and IL-6 (D) protein secretion into the culture media were determined by ELISA.Open bars correspond
to primary cultures of non-CF AMs. Solid bars correspond to primary cultures of CF AMs. The y-axis uses a logarithmic scale. Data are from six independent
experiments and represent mean6 SD. Unpaired t test was used to compare non-CF with CF AMs and paired t test was used to compare vehicle with LPS
treatment. *P, 0.05, **P, 0.01, ***P, 0.001. ND=not detected. The fold change of TNF-a mRNA from cells exposed to the vehicle is 0.96 0.1.
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response to LPS (Figure 2). To address
this issue, we used CFTRinh-172 to
pharmacologically inhibit putative CFTR
function (12, 38) in non-CF AMs. Treatment
of non-CF AMs for 72 hours with a maximal
dose of CFTRinh-172 (10 mM) (39) had no
effect on basal IL-6 mRNA levels and protein
secretion (Figures 4A and 4B). We also
determined the effect of 100 ng/ml LPS on
AMs pretreated with CFTRinh-172 for 72
hours. Although LPS significantly increased
IL-6 mRNA levels (Figure 4A) and IL-6
secretion (Figure 4B), pretreatment with
CFTRinh-172 did not potentiate the LPS-
induced inflammatory response (Figures 4A
and 4B). These data suggest that the robust
inflammatory phenotype with respect to
these cytokines of CF AMs is not linked to a
defective CFTR function.
AM Inflammatory Responses Are
Coupled to UPR Activation
To investigate whether the inflammatory
response of AMs is linked to activation of
IRE1a-dependent XBP-1 mRNA splicing
(XBP-1s), a UPR pathway implicated in
inflammatory responses of peripheral
macrophages (31), we compared the levels
of XBP-1s in non-CF versus CF AMs.
Under basal conditions, CF AMs exhibited
fourfold higher mRNA levels of XBP-1s
versus non-CF AMs. LPS up-regulated the
levels of XBP-1s in non-CF and CF AMs.
Notably, the absolute magnitude of
response of CF AMs to LPS was higher than
non-CF AMs (Figure 5).
We also evaluated the effect of
CFTRinh-172 on the mRNA levels of
XBP-1s. Under basal and LPS-stimulated
conditions, CFTRinh-172 did not affect
XBP-1s levels (Figure 6), suggesting that
loss of CFTR function per se was not
associated with the higher levels of XBP-1s

































Figure 3. Cystic fibrosis transmembrane
conductance regulator (CFTR) expression levels
in human alveolar macrophages (AMs). Bars
represent mRNA levels, determined by quantitative
reverse transcriptase polymerase chain reaction, of
CFTR in primary cultures of human bronchial
epithelial (HBE) cells and primary cultures of
human AMs. Data are expressed as fold change
relative to 18S mRNA and represent mean6 SD
from three independent experiments. Unpaired t
test was used for the statistical analysis. *P, 0.05,
HBE versus AMs. NS= not significant, CFTR levels















































LPSCFTRInh-172 CFTRInh-172 + LPS
Figure 4. Cystic fibrosis transmembrane conductance regulator (CFTR) inhibition does not induce an
inflammatory response in non-CF alveolar macrophages. Non-CF alveolar macrophages were
pretreated with CFTRinh-172 (10 mM) for 72 hours. Where applicable, 100 ng/ml LPS from
Pseudomonas aeruginosa was added during the last 6 hours. (A) Quantitative reverse transcriptase
polymerase chain reaction was used to determine the levels of IL-6 mRNA, which are expressed as
fold change relative to 18S mRNA. (B) IL-6 secretion into the culture media was evaluated by ELISA.
The y-axis uses a logarithmic scale. Data are from six independent experiments and represent
mean6 SD. Paired t test was used for the statistical analysis. *P, 0.05.
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To address whether the robust
inflammatory response coupled to higher
XBP-1s levels in CF AMs resulted from an
acquired response to the CF airway
infectious/inflammatory milieu, non-CF
AMs were exposed to SMM from human CF
airways (23–25). SMM up-regulated XBP-
1s, TNF-a, and IL-6 (Figures 7A–7C)
mRNA levels. Moreover, SMM up-
regulated TNF-a and IL-6 protein secretion
(Figures 7D and 7E), reproducing the
robust inflammatory phenotype of CF AMs
(Figure 2) associated with higher XBP-1s
levels (Figure 5).
Together, these data suggest that (1)
activation of IRE1a-dependent XBP-1s is
coupled with inflammatory responses in
both non-CF and CF AMs; (2) the higher
levels of XBP-1s in CF AMs are
proportionate to their robust inflammatory
phenotype; and (3) the greater
inflammatory response of CF AMs linked
to increased levels of XBP-1s is not
associated with the absence of CFTR





We next evaluated whether inhibition of
IRE1a-dependent XBP-1s decreased AM
cytokine secretion. The effect of the IRE1a
inhibitor 4m8C (40, 41) was tested on LPS-
induced IRE1a activation–dependent XBP-1s
and cytokine production in non-CF and CF
AMs. AMs were pretreated for 1 hour with
50 mM 4 m8C (40, 41) before induction of
inflammation with 100 ng/ml LPS. Our pilot
studies indicated that this dose promotes the
highest inhibition of LPS-induced IL-6
mRNA associated with IL-6 secretion (see
Figure E3). 4m8C significantly decreased LPS-
induced XBP-1s mRNA levels in non-CF and
CF AM cultures, as compared with LPS-
treated cultures that were not administered
4µ8C (Figure 8A). Pretreatment with 4m8C
significantly decreased LPS-increased TNF-a
mRNA levels by 57% and 83%, and IL-6
mRNA levels by 52% and 87%, respectively,
in non-CF and CF AMs (Figures 8B and 8C).
In addition, 4m8C significantly decreased
LPS-up-regulated TNF-a secretion by 45%
and 89%, and IL-6 secretion by 41% and 76%,
respectively, in non-CF and CF AM cultures
(Figures 8D and 8E). Notably, the decrease of
TNF-a and IL-6 protein secretion resulting
from 4m8C pretreatment was more marked in
CF versus non-CF AMs. These findings
suggest that 4m8C has antiinflammatory
properties resulting from its inhibitory effect
on IRE1a-mediated XBP-1s in AMs.
XBP-1 Is Required for LPS‐induced
AM Cytokine Production
The previously mentioned data indicate that


































Figure 5. Primary cultures of cystic fibrosis (CF) alveolar macrophages (AMs) express high levels of
X-box–binding protein-1 mRNA splicing (XBP-1s). Non-CF and CF AMs were stimulated for 6 hours
with 100 ng/ml LPS from Pseudomonas aeruginosa. Quantitative reverse transcriptase polymerase
chain reaction was used to determine the mRNA levels of XBP-1s. Data are expressed as fold change
relative to 18S mRNA and represent mean6 SD from six independent experiments. Open bars
correspond to primary cultures of non-CF AMs. Solid bars correspond to primary cultures of CF AMs.
Unpaired t test was used to compare non-CF with CF AMs, and paired t test was used to compare






























Vehicle LPSCFTRInh-172 CFTRInh-172 + LPS
Figure 6. Cystic fibrosis transmembrane conductance regulator (CFTR) inhibition does not induce
X-box–binding protein-1 mRNA splicing (XBP-1s) in primary cultures of non-CF alveolar
macrophages. Non-CF alveolar macrophages were pretreated with vehicle or CFTRinh-172 (10 mM)
for 72 hours and, when applicable, stimulated during the last 6 hours with 100 ng/ml LPS from
Pseudomonas aeruginosa. Quantitative reverse transcriptase polymerase chain reaction was used to
determine the mRNA levels of XBP-1s. Data are expressed as fold change relative to 18S mRNA and
represent mean6 SD from six independent experiments. Paired t test was used for the statistical
analysis. **P, 0.01.
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required for AM inflammatory responses,
and that XBP-1s mediates, at least in part,
the robust inflammatory phenotype of CF
AMs. To further evaluate the functional
role of XBP-1 in AM inflammatory
responses, a XBP-1-specific short hairpin
RNA (shRNA) was used to knockdown
XBP-1 in cultures of dTHP-1 cells. In the
absence of LPS stimulation, the XBP-1
shRNA knocked down the baseline mRNA
levels of XBP-1s by approximately 60% as
compared with control shRNA (Figure 9A).
LPS-up-regulated XBP-1s was significantly
blunted in XBP-1 shRNA expressing cells as
compared with control cells (Figure 9A).
The XBP-1 shRNA also blunted LPS-
increased TNF-a and IL-6 mRNA levels
(Figures 9B and 9C) and LPS-up-regulated
TNF-a and IL-6 protein secretion (Figures
9D and 9E), as compared with cells
expressing the control shRNA. Notably, the
inhibitory effect of the XBP-1 shRNA was
stronger for LPS-stimulated TNF-a versus
IL-6 secretion.
These findings suggested that in dTHP-1
cells the temporal and quantitative
regulation of TNF-a and IL-6 by XBP-1 is
different. To investigate this disparity, we
evaluated the mRNA levels and protein
secretion of TNF-a and IL-6 in control and
XBP-1 shRNA expressing dTHP-1 cells at
an earlier time point, after 3 hours LPS
stimulation. LPS up-regulated the mRNA
and protein secretion levels of TNF-a (see
Figure E4). The mRNA levels of TNF-a
were greatly decreased and TNF-a protein
secretion was not detectable after 3 hours
LPS in cells expressing the XBP-1 shRNA
(see Figure E4). At 3 hours postexposure to
LPS the IL-6 mRNA levels and IL-6
secretion were decreased in cells expressing
the XBP-1 shRNA, but these inhibitory
responses were not as robust as those for
LPS-induced TNF-a (see Figure E4). We
speculate that, unlike the rapid inhibition of
TNF-a transcription, there was a delay in
inhibition of IL-6 mRNA levels after 3
hours LPS in XBP-1 shRNA expressing
cells that produced a pool of IL-6 mRNAs
to be translated into IL-6 protein at 3 hours
and, then, at 6 hours LPS exposure.
To directly test the role of XBP-1s in
LPS-induced inflammatory responses
relevant to CF AMs, dTHP-1 cells stably
overexpressing a retroviral pQCXIN vector
(control), a pQCXIN vector expressing a
DN-XBP-1 construct, or a pQCXIN vector
expressing a XBP-1s construct (24, 27, 42)



















































































































Figure 7. The increased X-box–binding protein-1 mRNA splicing (XBP-1s) and the robust
inflammation of cystic fibrosis (CF) alveolar macrophages reflect an acquired response to the luminal
infectious and inflammatory milieu of CF airways. Primary cultures of non-CF alveolar macrophages
were exposed to phosphate-buffered saline (PBS) or supernatant from mucopurulent material (SMM;
1:3 dilution; pooled from the airways of five human CF lungs) for 3 hours. Quantitative reverse
transcriptase polymerase chain reaction was used to evaluate the levels of XBP-1s (A), tumor necrosis
factor (TNF)-a (B), and IL-6 (C) mRNA. Data are expressed as fold change relative to 18S mRNA.
TNF-a (D) and IL-6 (E) protein secretion into the culture media was determined by ELISA. Open bars
correspond to PBS exposure. Solid bars correspond to SMM exposure. The y-axis uses a logarithmic
scale for TNF-a and IL-6 mRNA and protein secretion. Data are from six independent experiments
and represent mean6 SD. Paired t test was used for the statistical analysis. *P, 0.05, **P, 0.01,
and ***P, 0.001.
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Vehicle LPS 4μ8C + LPS Vehicle LPS 4μ8C + LPS
Figure 8. Inhibition of inositol-requiring enzyme 1 a–dependent X-box–binding protein-1 mRNA splicing (XBP-1s) suppresses LPS-induced cytokine secretion in
primary cultures of alveolar macrophages (AMs). Non–cystic fibrosis (CF) and CF AMs were stimulated for 6 hours with 100 ng/ml LPS from Pseudomonas
aeruginosa in the absence or presence of the Inhibition of inositol-requiring enzyme 1 a inhibitor 8-formyl-7-hydroxy-4-methylcoumarin (4m8C) (50 mM; 1 h
pretreatment). Quantitative reverse transcriptase polymerase chain reaction was used to evaluate the levels of XBP-1s (A), tumor necrosis factor (TNF)-a (B), and IL-
6 (C) mRNA. Data are expressed as fold change relative to 18SmRNA. TNF-a (D) and IL-6 (E) secretion into the culture media was determined by ELISA.Open bars
correspond to primary cultures of non-CF AMs. Solid bars correspond to primary cultures of CF AMs. The y-axis uses a logarithmic scale for TNF-a and IL-6 mRNA
and protein secretion. Data are from five independent experiments and represent mean6 SD. Unpaired t test was used to compare non-CF with CF AMs and
paired t test was used to compare the different treatments. *P,0.05, **P,0.01, and ***P,0.001. ND=not detected.
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Figure 9. Knockdown of X-box–binding protein-1 (XBP-1) suppresses LPS-induced XBP-1 mRNA splicing (XBP-1s) and cytokine production.
Macrophage-like differentiated THP-1 cultures stably expressing a control vector or a XBP-1-specific short hairpin RNA (shRNA) were stimulated during
6 hours with 100 ng/ml LPS from Pseudomonas aeruginosa. Quantitative reverse transcriptase polymerase chain reaction was used to evaluate the levels
of XBP-1s (A), tumor necrosis factor (TNF)-a (B), and IL-6 (C) mRNA. Data are expressed as fold change relative to 18S mRNA. TNF-a (D) and IL-6
(E) protein secretion into the culture media was determined by ELISA. The y-axis uses a logarithmic scale for TNF-a and IL-6 mRNA and protein
secretion. Data are from six independent experiments and represent mean6 SD. One-way analysis of variance was used for the statistical analysis.
***P, 0.001. ND = not detected. The fold change of IL-6 mRNA from dTHP-1 cells expressing XBP-1 shRNA and exposed to vehicle is 0.36 0.3.
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Figure 10. LPS-dependent cytokine production is mediated by X-box–binding protein-1 mRNA splicing (XBP-1s). Macrophage-like differentiated THP-1
cultures stably expressing a control pQCXIN vector, a pQCXIN vector containing a dominant negative XBP-1 (DN-XBP-1), or a pQCXIN vector containing
XBP-1s were stimulated for 6 hours with vehicle or 100 ng/ml LPS from Pseudomonas aeruginosa. The levels of XBP-1s (A), tumor necrosis factor (TNF)-a
(B), and IL-6 (C) mRNA were analyzed by quantitative reverse transcriptase polymerase chain reaction and expressed as fold change relative to 18S
mRNA. TNF-a (D) and IL-6 (E) protein secretion into the culture media was determined by ELISA. The y-axis uses a logarithmic scale for TNF-a and IL-6
mRNA and protein secretion. Data are from six independent experiments and represent mean6 SD. One-way analysis of variance was used for the
statistical analysis. *P, 0.05, **P, 0.01, and ***P, 0.001 spliced XBP-1 or DN-XBP-1 expressing cells versus control cells. ND = not detected. The fold
changes of TNF-a mRNA in dTHP-1 cells expressing control, DN-XBP, and XBP-1s and exposed to vehicle are 0.76 0.5, 0.36 0.1, and 16 0.5,
respectively. The fold changes of IL-6 mRNA in dTHP-1 cells expressing control and DN-XBP-1 and exposed to vehicle are 0.86 0.5 and 0.36 0.15,
respectively.
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in control cultures, and this response was
attenuated in cells expressing the DN-XBP-
1 (Figure 10A). The inhibitory effect of the
DN-XBP-1 was also observed for LPS-up-
regulated TNF-a and IL-6 mRNA levels
(Figures 10B and 10C) and protein
secretion (Figures 10D and 10E).
Assessment of XBP-1s mRNA confirmed
that XBP-1s mRNA levels were increased in
dTHP-1 cell overexpressing XBP-1s
(Figure 10A). Importantly, LPS-increased
XBP-1s, TNF-a, and IL-6 mRNA levels
(Figures 10A–10C) and TNF-a and IL-6
protein secretion (Figures 10D and 10E)
were potentiated in dTHP-1 cells
overexpressing XBP-1s. These findings
further establish the functional role of
XBP-1s in AM inflammatory responses.
Discussion
AMs are critical for the maintenance of
airway homeostasis, but their role in CF lung
disease has not been fully studied. AMs clear
the air spaces of infectious, toxic, and
allergic particles; regulate innate alveolar
defense against infection by secreting
cytokines (43); and initiate inflammatory
responses by recruiting activated
neutrophils into air spaces (44). However,
AM dysregulation could impair resolution
of inflammation via a failure to act as
suppressor cells, leading to chronic
pulmonary infection and inflammation
(38). Furthermore, in chronically
obstructed CF airways, the persistent
exposure of AMs to the infectious/
inflammatory milieu can lead to persistent
and, possibly, inappropriate activation of
their inflammatory responses, contributing
to lung damage.
Activation of the UPR has been
implicated in airway epithelial inflammatory
responses characteristic of CF airways (25,
26). Freshly isolated airway epithelia from
chronically infected/inflamed human CF
lungs exhibit increased levels of XBP-1s,
and XBP-1s is required for cytokine
production by inflamed human airway
epithelia (24). These findings suggested that
the IRE1a–XBP-1 arm of the UPR plays a
pivotal role in CF airway epithelial
inflammation. Based on the role of XBP-1s
in inflammatory responses of airway
epithelia, we hypothesized that AMs from
chronically infected/inflamed human CF
lungs also exhibit robust inflammation
(e.g., increased basal and LPS-stimulated
cytokine production), and XBP-1s is
required for these responses.
Our data demonstrate that primary
cultures of human CF AMs indeed exhibit a
robust inflammatory phenotype (Figure 2).
The greater inflammatory response of CF
AMs required IRE1a activation–dependent
generation of XBP-1s based on these
findings: (1) increased XBP-1s levels were
associated with increased LPS-induced
cytokine production (Figures 5, 8–10); (2)
treatment with the IRE1a inhibitor 4µ8C
reduced LPS-increased XBP-1s, TNF-a,
and IL-6 mRNA levels and TNF-a and IL-6
protein secretion (Figure 8); (3) knockdown
of XBP-1 inhibited LPS-increased XBP-1s,
TNF-a, and IL-6 mRNA levels and TNF-a
and IL-6 protein secretion (Figure 9); (4)
overexpression of DN-XBP-1 decreased
LPS-up-regulated XBP-1s and inhibited
LPS-induced TNF-a and IL-6 production
(Figure 10); and (5) macrophage cultures
overexpressing XBP-1s exhibited increased
LPS-induced TNF-a and IL-6 production
(Figure 10).
The baseline levels of IL-6 and TNF-a
mRNA and protein secretion in CF AMs
were higher than non-CF AMs, and the
absolute increase after LPS stimulation was
greater in CF than non-CF AMs (Figure 2).
The same effect was observed with the
mRNA levels of XBP-1s (Figure 5). These
data suggest that native CF AMs exhibit
higher XBP-1s-mediated TNF-a and IL-6
production in response to acute and
chronic exposure to bacterial infection (and
LPS) in CF lungs. Note, the in vitro
exposure to LPS resulted in a lower fold
increase of these genes in CF versus non-CF
AMs, perhaps reflecting the higher basal
levels in CF AMs.
It is generally accepted that LPS
promotes cytokine production via activation
of the transcription factor nuclear factor
(NF)-kB during innate immune responses
to pathogens (45). Our study suggests that
TLR activation by LPS triggers IRE1a
activation–dependent XBP-1 mRNA
splicing, which identifies a novel pathway
required for LPS-induced cytokine
production and secretion in human AMs.
These findings agree with a report
describing the role of XBP-1 in innate
immune responses of peripheral
macrophages based on the observations that
transgenic mice deficient for XBP-1 in
peripheral macrophages exhibited decreased
inflammatory responses (31). This study
also suggested that LPS (via TLR-4) and
IRE1a/XBP-1 are interconnected and
cooperate to maximize innate immune
responses to pathogens (31). Activation of
TLRs can couple to activation of IRE1a via
TRAF6- and NOX2-dependent pathways
(46). The activated IRE1a interacts via
TRAF2 with the IKK complex and with
ASK and JNK protein kinases (47), thereby
modulating activation of the transcription
factors NF-kB and AP-1 (48). Deletion of
the IRE1a gene reduces proinflammatory
cytokine production because of impairment
of JNK activation and the lack of functional
XBP‐1s in bone marrow–derived
macrophages from IRE1a knockout mice
(41). In parallel, the XBP-1s resulting from
IRE1a activation can directly promote
transcriptional up-regulation of cytokine
genes, contributing to maximal cytokine
production (46). These findings suggest
that the two mechanisms (e.g., IRE1a-
dependent XBP-1s and IRE1a-mediated
NF-kB and/or JNK activation) can coexist
with canonical LPS–NF-kB signaling in
AMs. Additional studies are necessary to
define the pathways for IRE1a-regulated
NF-kB and JNK activation in AM
inflammatory responses.
The IRE1a inhibitor 4m8C, a synthetic
coumarin derivative, blocks substrate access
to the active site of IRE1a and selectively
inactivates IRE1a-dependent mRNA
splicing of XBP-1 (40). Several studies have
shown that coumarin compounds have
strong antiinflammatory effects (49, 50),
including findings suggesting that
coumarin compounds can also target
NF-kB (51) and mitogen-activated protein
kinase (52). Our data demonstrated that
4m8C decreased the levels of XBP-1s and
suppressed LPS-induced cytokine
production (Figure 8). Additional studies
are needed to expand the understanding
of the mechanism underlying the
antiinflammatory action of 4m8C in CF
airways disease.
Previous studies have reported that
CFTR is expressed in murine and human
AMs (12) and CFTR malfunction in
macrophages is directly linked with the
robust inflammation in CF (14–16). It has
been suggested that altered properties of
murine CF AMs may contribute to
uncontrolled lung inflammation (14, 15).
For instance, it has been reported that
functional CFTR is critical for regulation
of phagosomal pH in murine AMs (12),
and CFTR-deficient macrophages fail to
acidify lysosomes and phagolysosomal
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compartments and display altered
bactericidal activity (13, 16, 19, 53).
Furthermore, malfunction of CFTR and
excessive inflammation in human and
murine macrophages have been associated
with a higher proinflammatory cytokine
secretion (14, 38).
Our findings suggest that the robust
inflammatory response of human CF AMs
reflects an adaptive response to the chronic
infectious/inflammatory milieu of CF
airways in vivo and is independent of
CFTR function, based on the following
observations. First, as compared with the
levels of CFTR expression in HBE
cultures, the levels of CFTR expression in
non-CF AMs are close to zero (Figure 3).
Second, pretreatment of non-CF AMs
with CFTRinh-172 neither increased
basal PS-induced cytokine production
(Figure 4). Third, exposure of non-CF
AMs to SMM, the infectious/inflammatory
milieu of native CF airways, reproduced
the robust inflammatory phenotype of CF
AMs coupled to larger XBP-1s levels
(Figure 7). Hence, although very low levels
of CFTR expression may be important for
regulation of other AM functions (12, 13),
the present studies indicate that the
exaggerated inflammation of primary
cultures of human CF AMs is not linked to
defective CFTR function.
In summary, our study revealed that
AMs harvested from chronically infected/
inflamed human CF lungs exhibit increased
cytokine production and secretion. These
data indicate that this response reflects a
cellular adaptation to the infectious/
inflammatory milieu of CF airways and
requires activation of IRE1a/XBP-1. The
observation that CF AMs exhibit a larger
response to LPS-induced inflammation in
an XBP-1s–dependent manner supports the
notion that XBP-1s is a positive regulator of
genes resulting from TLR-4 activation in
AMs. These findings offer the proof-of-
principle that targeting the IRE1a/XBP-1
pathway may be a therapeutic strategy to
decrease the robust inflammatory response
of AMs in chronically infected/inflamed CF
lungs. This view is supported by recent
studies suggesting that targeting the
IRE1a/XBP-1 pathway may improve
clinical outcomes for patients with drug-
resistant pre-B-cell acute lymphoblastic
leukemia (54) and patients with multiple
myeloma (55). n
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